About

About Enzene Inc. About Enzene Enzene is an end-to-end CDMO with services spanning discovery, development, and commercial supply, operating integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next-generation biologics technologies, Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology, which was the first fully-connected continuous manufacturing™ (FCCM™) platform validated for commercial biologics supply. We partner with innovators and biosimilar developers to deliver accelerated time-to-market, increased production yields, and cost reductions across a broad range of biologic modalities. Committed to pushing the boundaries of biologics manufacturing innovation, Enzene is striving to reduce monoclonal antibody production costs to below $40 per gram by 2025. Our microbial and mammalian drug substance plants, as well as our sterile fill & finish plant in India are EU-GMP certified. Enzene is a leading global continuously innovative development and manufacturing organization (CIDMO). The company was founded on a belief that we have a responsibility to positively impact healthcare around the world by providing the technological expertise, passion for innovation, and dedication to helping clients bring accessible and affordable products to market. Built on a proven history of successful commercial launches and a strong early-stage product pipeline, Enzene continues to disrupt the CDMO industry with novel processes that improve quality and productivity while reducing costs and carbon footprint. Our comprehensive capabilities encompass R&D, analytics, and GMP manufacturing, empowering us to offer innovative, high-quality solutions that meet diverse client needs. By providing end-to-end CDMO services for biologics, from cell line development to fill & finish for complex molecules, we are a versatile CDMO partner for our clients across a wide array of modalities. And with multiple manufacturing lines at our Pune, India and New Jersey, USA facilities, Enzene is strategically positioned to meet the escalating demand for biologics and biosimilars across both hemispheres. Additionally, our proprietary continuous manufacturing technology, EnzeneX™, sets us apart as visionaries in the industry, driving healthcare advancement and setting new standards for biologics development and manufacturing. The EnzeneX™ platform optimizes quality, efficiency, and flexibility while supporting cost-effective, sustainable production of top-tier biologics, thereby improving global patient access. At Enzene, we are leaders who seek to solve today’s biotech challenges as well as tomorrow’s by upholding our core values of innovation, integrity, excellence, entrepreneurship, candor, and respect.